In 2020, the European Commission announced its new "Pharmaceutical Strategy for Europe" for the coming years. The new legislation is due to be published in 2023.
- One aspect of the new "Pharmaceutical Strategy for Europe" involves a major revision of the European Union's (EU) general pharmaceutical legislation, and its legislation on rare diseases and paediatric drugs. In order to prepare these documents and initiatives, the Commission organised several public consultations beforehand.
- This article consists of excerpts from the Commission's proposals, as well as excerpts from contributions submitted to the Commission's public consultations by Prescrire and a European alliance of civil society organisations, in which Prescrire participated.
©Prescrire 1 December 2022
Source: "Impending changes to European pharmaceutical regulations: part I" Prescrire International 2022; 31 (243): 302-304. Free.
Enjoy full access to Prescrire International, and support independent information
|